Literature DB >> 8755825

Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides.

U Galili1, K L Matta.   

Abstract

Rejection of pig-to-human or pig-to-primate xenografts is mediated by the natural anti-Gal antibody, which interacts with alpha-galactosyl epitopes (i.e., Gal alpha1-3Gal beta1-4GlcNAc-R) abundantly expressed on porcine cells. The objective of this study was to determine the ability of various synthetic oligosaccharides to inhibit the binding of anti-Gal IgG molecules to porcine endothelial cells in vitro. Such inhibition ultimately may help to reduce or to prevent the in vivo antibody-dependent cell cytotoxicity (ADCC) reaction. In the absence of complement-mediated hyperacute rejection, the ADCC induced by anti-Gal IgG molecules is likely to cause the chronic rejection of xenografts. The synthetic free alpha-galactosyl epitope (Gal alpha1-3Gal beta1-4GlcNAc) was found to be 300-fold more effective than melibiose or alpha-methyl galactoside in inhibiting anti-Gal binding to porcine endothelial cells, and to prevent >90% of the antibody binding at a concentration of 1 mM. The disaccharide Gal alpha1-3Gal was ten-fold less effective than the free alpha-galactosyl epitope. Accordingly, the affinity of the disaccharide to anti-Gal, as measured by equilibrium dialysis, was seven-fold lower than that of the trisaccharide. The effective concentration of oligosaccharides inhibiting anti-Gal is independent of the antibody affinity, but is dependent on the concentration of the antibody. Based on the small difference in affinity between Gal alpha1-3Gal beta1-4GlcNAc and Gal alpha1-3Gal beta1-4GIc, and the large difference in the price of N-acetyllactosamine vs. lactose, it is suggested that lactose may be considered as an appropriate starting material for synthesizing large amounts of a trisaccharide that effectively neutralizes anti-Gal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755825     DOI: 10.1097/00007890-199607270-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay.

Authors:  Haruko Ogawa; Uri Galili
Journal:  Glycoconj J       Date:  2006-11-18       Impact factor: 2.916

2.  Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer.

Authors:  Andreas G Katopodis; Richard G Warner; Rudolf O Duthaler; Markus B Streiff; Armin Bruelisauer; Olivier Kretz; Birgit Dorobek; Elke Persohn; Hendrik Andres; Alain Schweitzer; Gebhard Thoma; Willy Kinzy; Valerie F J Quesniaux; Emanuele Cozzi; Hugh F S Davies; Rafael Mañez; David White
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

Authors:  G L Palmisano; P L Tazzari; E Cozzi; A Bolognesi; L Polito; M Seveso; E Ancona; F Ricci; R Conte; F Stirpe; G B Ferrara; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 4.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 5.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

6.  Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.

Authors:  Sara Olivera-Ardid; Daniel Bello-Gil; Alexander Tuzikov; Ricardo N Araujo; Yara Ferrero-Alves; Blanca Esther García Figueroa; Moisés Labrador-Horrillo; Ana L García-Pérez; Nicolai Bovin; Rafael Mañez
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

7.  Tick Bites Induce Anti-α-Gal Antibodies in Dogs.

Authors:  Adnan Hodžić; Lourdes Mateos-Hernández; Michael Leschnik; Pilar Alberdi; Ryan O M Rego; Marinela Contreras; Margarita Villar; José de la Fuente; Alejandro Cabezas-Cruz; Georg Gerhard Duscher
Journal:  Vaccines (Basel)       Date:  2019-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.